Pharma BD Deal Intelligence
Bristol-Myers Squibb's $4.1 billion all-cash acquisition of Turning Point Therapeutics secured repotrectinib (Augtyro), a next-generation ROS1/NTRK inhibitor for ROS1-positive non-small cell lung cancer. The deal handed BMS a differentiated targeted-oncology asset in a precision lung cancer niche, strengthening its solid tumor pipeline beyond its existing immuno-oncology base.
Bristol Myers Squibb's acquisition strategy continued with the Turning Point Therapeutics buyout, part of a broader push to strengthen its precision oncology…
FDA granted accelerated approval to repotrectinib (Augtyro) for adult and pediatric patients 12+ with NTRK gene fusion-positive solid tumors on June 13, 2024.
EMA EPAR: Augtyro (repotrectinib) granted EU conditional marketing authorisation on 13 January 2025 for ROS1+ advanced NSCLC and NTRK+ solid tumors.
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Bristol-Myers Squibb acquired Turning Point Therapeutics for approximately $4.1 billion ($76.00 per share) in an all-cash tender offer, gaining repotrectinib (Augtyro), a next-generation ROS1/NTRK inhibitor with differentiated activity in ROS1-positive non-small cell lung cancer.
NTRK fusion-positive solid tumors constitute a tissue-agnostic, genomically defined niche (~0.3% incidence) with two entrenched 1L TRK inhibitors and one next-gen entrant addressing resistance. First-generation TRK inhibitors: larotrectinib (Vitrakvi, Bayer/Loxo) received tissue-agnostic FDA approval in 2018; entrectinib (Rozlytrek, Roche) approved 2019 for NTRK+ solid tumors and ROS1+ NSCLC. Rozlytrek generated CHF 237M in 2023 per Roche IR; Vitrakvi remains sub-$200M globally. Both face on-target resistance (NTRK G595R, G623R solvent-front mutations). Next-generation TRK inhibitors: repotrectinib (Augtyro, BMS) received FDA approval June 2024 for TRK-resistant/naive NTRK+ solid tumors based on TRIDENT-1 after its June 2024 approval — the only compound with documented activity against solvent-front mutations. Selitrectinib (Loxo-195, Bayer) is discontinued. Taletrectinib (Ibtrozi, Nuvation Bio) approved June 2025 is ROS1-focused but has NTRK activity in early data. Pan-TRK/ROS1 investigational: zidesamtinib (NVL-520, Nuvalent) is in pivotal ROS1 trials with NTRK expansion. Commercial lead takeaway: Augtyro's 2L post-TRKi positioning is defensible near-term, but pricing will be rationed by the ultra-low prevalence and NGS testing-gated funnel.
ROS1+ NSCLC (~1-2% of NSCLC) is a defined niche with three generations of TKIs competing on CNS penetration and solvent-front resistance coverage. First-generation ROS1 TKIs: crizotinib (Xalkori, Pfizer) retained 1L standing historically but shows weak CNS activity; ceritinib (Zykadia, Novartis) has limited ROS1 label use. Second-generation ROS1/TRK TKIs: entrectinib (Rozlytrek, Roche) was the preferred 1L for CNS disease prior to 2024, generating CHF 237M globally in 2023 per Roche IR; lorlatinib (Lorbrena, Pfizer — ALK-primary) has investigational ROS1 activity. Next-generation macrocyclic ROS1 TKIs: repotrectinib (Augtyro, BMS) received FDA approval November 2023 for TKI-naive and post-crizotinib ROS1+ NSCLC based on TRIDENT-1 (ORR 79% naive, 38% pre-treated) with activity against G2032R solvent-front mutation; taletrectinib (Ibtrozi, Nuvation Bio) gained FDA approval June 2025 with similar activity profile including G2032R coverage. Investigational: zidesamtinib (NVL-520, Nuvalent) showed selective ROS1 activity in ARROS-1 with TRK-sparing profile targeting improved tolerability. Commercial lead takeaway: Augtyro and Ibtrozi will contest the TKI-naive 1L category while Xalkori cedes share; zidesamtinib data will set the 2026+ benchmark. Pricing in this ~2,500-patient/year US niche scales via oral compliance and NGS-positive testing depth.
BMS completed $4.1B acquisition of Turning Point Therapeutics ($76/share), gaining repotrectinib, a next-gen ROS1/TRK inhibitor for NSCLC.
FDA approved Augtyro for ROS1-positive NSCLC, validating the $4.1B acquisition. Analysts project $1.4B peak sales in first-line setting.
FDA granted accelerated approval for Augtyro in NTRK gene fusion-positive locally advanced/metastatic solid tumors (TKI-naive and pretreated), based on TRIDENT-1. Second U.S. indication after ROS1+ NSCLC, broadening the franchise to tissue-agnostic precision oncology.
European Commission granted conditional marketing authorisation for Augtyro across ROS1+ advanced NSCLC and NTRK+ solid tumors, extending the Turning Point franchise to the EU on TRIDENT-1 / CARE data.
Augtyro secured FDA approval 16 months after close, ramping commercially. NTRK expansion underway. $1.4B+ peak sales projected; $4.1B price appears reasonable.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Bristol-Myers Squibb Company / Turning Point Therapeutics Inc. (this deal) | 2022 | $4.1B | 70 |
| Bristol-Myers Squibb Company / Medarex Inc. | 2009 | $2.4B | 92 |
| Bristol-Myers Squibb Company / Celgene Corporation | 2019 | $74.0B | 77 |
| Bristol-Myers Squibb Company / MyoKardia Inc. | 2020 | $13.1B | 76 |
| Bristol-Myers Squibb Company / Karuna Therapeutics | 2023 | $14.0B | 76 |
| Bristol-Myers Squibb Company / Ono Pharmaceutical Co., Ltd. | 2011 | — | 76 |
| Bristol-Myers Squibb Company / SystImmune Inc. | 2023 | $8.4B | 71 |
← Browse all deals · How we score deals
More: 2022 deals · Bristol-Myers Squibb Company deals · Oncology deals